Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

Herbal and nutritional supplement direct seller has reached 85% solar power use at its US facilities while also reducing landfill waste from those sites more than 90%, cutting its US shipping routes by half and consolidating four distribution centers in Europe into one operating on wind power.

A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.

FDA leadership has generally seemed apprehensive of going too hard on companies that don’t meet clinical trial diversity goals, but some industry insiders say a stronger FDA is needed to spark real change. Delayed guidance could indicate if the agency will change course.